TY - JOUR
T1 - Therapeutic applications of synthetic nucleic acid aptamers
AU - Poolsup, Suttinee
AU - Kim, Chu Young
N1 - Funding Information:
This work was supported by institutional funding from the University of Texas at El Paso.
Publisher Copyright:
© 2017 Elsevier Ltd
PY - 2017/12
Y1 - 2017/12
N2 - It is possible to generate oligonucleotide aptamers for a wide variety of target molecules using a process known as Systematic Evolution of Ligands by Exponential Enrichment. Researchers have successfully generated aptamers which recognize specific metal ions, small chemical compounds, peptides, proteins, saccharides, and even whole cells. Aptamers show much promise as future therapeutics and as drug targeting agents. A particularly active area of aptamer research in the past two years was development of aptamer based cancer therapeutics and development of aptamer based cancer drug delivery systems. Aptamers were also used to address inflammatory diseases, infectious diseases, cardiovascular diseases, and eye diseases.
AB - It is possible to generate oligonucleotide aptamers for a wide variety of target molecules using a process known as Systematic Evolution of Ligands by Exponential Enrichment. Researchers have successfully generated aptamers which recognize specific metal ions, small chemical compounds, peptides, proteins, saccharides, and even whole cells. Aptamers show much promise as future therapeutics and as drug targeting agents. A particularly active area of aptamer research in the past two years was development of aptamer based cancer therapeutics and development of aptamer based cancer drug delivery systems. Aptamers were also used to address inflammatory diseases, infectious diseases, cardiovascular diseases, and eye diseases.
UR - http://www.scopus.com/inward/record.url?scp=85019975066&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019975066&partnerID=8YFLogxK
U2 - 10.1016/j.copbio.2017.05.004
DO - 10.1016/j.copbio.2017.05.004
M3 - Review article
C2 - 28582756
AN - SCOPUS:85019975066
SN - 0958-1669
VL - 48
SP - 180
EP - 186
JO - Current Opinion in Biotechnology
JF - Current Opinion in Biotechnology
ER -